Jones Hill Capital LP
Filing Date
Mar 31, 2026
Global Rank
#2,420
/ 8,232
Top Industry
Biotechnology
90.0%
3Y Alpha vs SPY
-129.5%
Period ended 2 months ago
Filed May 14, 2026 · 31d
Clone Performance
May 2026–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
+2.0%
SPY
+0.2%
Annualised alpha
—
Max drawdown
−8.5%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
26 positions · as of Mar 31, 2026Top Position
15.4%
of portfolio value
Top 5
46.3%
of portfolio value
Top 10
73.1%
of portfolio value
HHI
701
Diversified
Sector Breakdown
As of Mar 31, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $466,471,277 |
26 positions ·
$466,471,277 total
· as of Mar 31, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
First | 1,268,390 | $71,651,351 | 15.36% | |
| VRTX |
Vertex Pharmaceuticals Inc / Ma
Healthcare
|
First | 108,603 | $48,495,583 | 10.40% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
First | 644,831 | $37,471,129 | 8.03% | |
| NUVL |
Nuvalent, Inc.
Healthcare
|
First | 300,830 | $30,820,033 | 6.61% | |
| CAPR |
Capricor Therapeutics, Inc.
Healthcare
|
First | 909,207 | $27,639,892 | 5.93% | |
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
First | 521,237 | $27,479,614 | 5.89% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
First | 1,260,136 | $25,064,105 | 5.37% | |
| ANIP |
Ani Pharmaceuticals Inc
Healthcare
|
First | 318,591 | $24,499,647 | 5.25% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
First | 1,165,557 | $24,418,419 | 5.23% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
First | 593,040 | $23,247,168 | 4.98% | |
| AMLX |
Amylyx Pharmaceuticals, Inc.
Healthcare
|
First | 1,598,794 | $22,223,236 | 4.76% | |
| ARGX |
Argenx SE
Healthcare
|
First | 25,995 | $18,982,848 | 4.07% | |
| FULC |
Fulcrum Therapeutics, Inc.
Healthcare
|
First | 1,771,926 | $13,590,672 | 2.91% | |
| VIR |
Vir Biotechnology, Inc.
Healthcare
|
First | 1,198,213 | $10,735,988 | 2.30% | |
| NUVB |
Nuvation Bio Inc.
Healthcare
|
First | 2,383,031 | $10,223,202 | 2.19% | |
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
First | 140,843 | $6,908,349 | 1.48% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
First | 513,053 | $6,700,472 | 1.44% | |
| MANE |
Veradermics, Inc
Healthcare
|
First | 100,843 | $6,368,235 | 1.37% | |
| TNXP |
Tonix Pharmaceuticals Holding Corp.
Healthcare
|
First | 452,116 | $6,216,595 | 1.33% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
First | 100,593 | $4,848,582 | 1.04% | |
| TRDA |
Entrada Therapeutics, Inc.
Healthcare
|
First | 374,010 | $4,720,006 | 1.01% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
First | 167,014 | $4,718,145 | 1.01% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
First | 370,175 | $4,416,187 | 0.95% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
First | 342,752 | $2,385,553 | 0.51% | |
| SLN |
Silence Therapeutics plc
Healthcare
|
First | 301,604 | $1,589,453 | 0.34% | |
| AVBP |
ArriVent BioPharma, Inc.
Healthcare
|
First | 45,809 | $1,056,813 | 0.23% |